TheraRadar
← Back
Data updated: Mar 29, 2026

IOMED

OncologyMetabolicImmunology
Pharma

IOMED is a pharmaceutical company focused on Oncology, Metabolic, Immunology.

1995
Since
1
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 62%
0 drugs Phase 3: 13 Phase 2: 23 Phase 1: 60
Metabolic 15%
0 drugs Phase 3: 5 Phase 2: 6 Phase 1: 7
Immunology 9%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 8
Ophthalmology 7%
0 drugs Phase 3: 2 Phase 2: 4 Phase 1: 2
Respiratory 6%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 4

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Oncology, Immunology, Ophthalmology, Respiratory
Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory
Roche big-pharma
Oncology, Ophthalmology, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology